CT | Jotup

AdventHealth Opening New Off-Site Emergency Department in Winter Haven

Retrieved on:

星期四, 五月 9, 2024

HuntonBrady, Florida State Road 540, Hospital, Legoland, Partnership, Garden, HAVEN, Patient, AdventHealth, Multimedia, Tourism

WINTER HAVEN, Fla., May 9, 2024 /PRNewswire/ -- Hospital leaders, local government officials and members of the business community took the next step in bringing better access to high-quality emergency care to Winter Haven with the ribbon-cutting ceremony for the new AdventHealth Winter Haven ER on Thursday, May 9, 2024.

Key Points:

The AdventHealth Winter Haven ER has 24 exam rooms, including a resuscitation room, a bariatric room, an isolation room, obstetrics-friendly room and pediatric-friendly rooms.
The AdventHealth Winter Haven ER marks the first phase of our commitment to expanding emergency care in Winter Haven.
The AdventHealth Winter Haven project is just the latest in the longtime partnership between AdventHealth and Robins & Morton.
The AdventHealth Winter Haven ER, a department of AdventHealth Heart of Florida, will open to new patients by the end of May 2024.

Veterinary Imaging Market Size Projected to Reach USD 4,306.6 Million by 2034: Future Market Insights, Inc.

Retrieved on:

星期四, 五月 9, 2024

NEWARK, Del., May 9, 2024 /PRNewswire/ -- The veterinary imaging market has been gaining significant traction globally, with a projected value of USD 2,272.8 million in 2024 and an estimated value of USD 4,306.6 million by 2034, developing at a CAGR of 6.6%. The rising demand for animal healthcare services, growing pet ownership, and increasing awareness about the importance of animal health primarily drive this growth.

Key Points:

Veterinary imaging equipment is further categorized as radiography (X-ray), ultrasound imaging, magnetic resonance imaging, computed tomography, video endoscopy imaging, and other systems.
From its estimated value of US$ 1,465.4 million in 2024, the market is expected to reach US$ 2,319.6 million by 2034.
According to recent research by Future Market Insights, app-based solutions dominate the market, holding a share of approximately 57.7% in 2022.
The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.

Veterinary Imaging Market Size Projected to Reach USD 4,306.6 Million by 2034: Future Market Insights, Inc.

Retrieved on:

星期四, 五月 9, 2024

NEWARK, Del., May 9, 2024 /PRNewswire/ -- The veterinary imaging market has been gaining significant traction globally, with a projected value of USD 2,272.8 million in 2024 and an estimated value of USD 4,306.6 million by 2034, developing at a CAGR of 6.6%. The rising demand for animal healthcare services, growing pet ownership, and increasing awareness about the importance of animal health primarily drive this growth.

Key Points:

Veterinary imaging equipment is further categorized as radiography (X-ray), ultrasound imaging, magnetic resonance imaging, computed tomography, video endoscopy imaging, and other systems.
From its estimated value of US$ 1,465.4 million in 2024, the market is expected to reach US$ 2,319.6 million by 2034.
According to recent research by Future Market Insights, app-based solutions dominate the market, holding a share of approximately 57.7% in 2022.
The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on:

星期四, 五月 9, 2024

FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points:

510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on:

星期四, 五月 9, 2024

FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points:

510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

Qualys to Speak at Upcoming Investor Conference

Retrieved on:

星期四, 五月 9, 2024

CFO, Conference, Cryptocurrency

FOSTER CITY, Calif., May 9, 2024 /PRNewswire/ -- Qualys, Inc. (NASDAQ: QLYS), a pioneer and leading provider of disruptive cloud-based IT, security and compliance solutions, today announced that management will participate in a fireside chat and host one-on-one meetings with interested investors at the following conference:

Key Points:

FOSTER CITY, Calif., May 9, 2024 /PRNewswire/ -- Qualys, Inc. (NASDAQ: QLYS), a pioneer and leading provider of disruptive cloud-based IT, security and compliance solutions, today announced that management will participate in a fireside chat and host one-on-one meetings with interested investors at the following conference:
William Blair's 44th Annual Growth Stock Conference.
Sumedh Thakar, president and CEO, and Joo Mi Kim, CFO, will host one-on-one meetings and participate in a fireside chat in Chicago, Illinois on Wednesday, June 5, 2024 at 12:00pm CT.
At the time of the fireside chat, a live webcast will be accessible from the investor relations page of the Qualys website at https://investor.qualys.com/events-presentations .
Following the event, a replay will be made available at the same location.

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Retrieved on:

星期四, 五月 9, 2024

This approach could potentially be adapted for diagnosis of other neurological conditions.

Key Points:

This approach could potentially be adapted for diagnosis of other neurological conditions.
WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.
As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
The Danaher Beacon for Brain Injury Diagnostics is the sixth collaboration in the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

Associated Capital Group, Inc. Reports Increased First Quarter Book Value

Retrieved on:

星期四, 五月 9, 2024

Arbitrage, Equity, London Stock Exchange, Investment, Research, Investment fund, AC, Finance

GREENWICH, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (“AC” or the “Company”), a diversified financial services company, today reported its financial results for the first quarter ended March 31, 2024.

Key Points:

Private Equity accounted for 19% of M&A activity in the first quarter as total value reached $154 billion, an increase of 13% compared to 2023.
Associated Capital Group's plan is to accelerate the use of its capital.
During the first quarter, AC repurchased 117,354 Class A shares, for $3.9 million, at an average price of $33.63 per share.
At March 31, 2024, there were 21.420 million shares outstanding, consisting of 2.469 million Class A shares and 18.951 million Class B shares outstanding.

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Retrieved on:

星期四, 五月 9, 2024

Congress, CDK, Proteolysis, HER2, Breast cancer, Oncology, ARVN, ESMO, Chimera, Patient, Team Impulse, Poster, Clinical trial, PROTAC

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.

Key Points:

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.
Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Poster session details are as follows:
Time: 12:00 – 1:00 p.m. CET/ 6:00 – 7:00 a.m.
ET
Poster Title and Number: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results, Poster 218P
Presentation Type and Abstract Number: Abstract, 453
Poster Title and Number: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer, Poster 264
Presentation Type and Abstract Number: Trial-in-Progress (TiP), 488

Sachem Capital Sets Dates for First Quarter 2024 Earnings Release and Conference Call

Retrieved on:

星期四, 五月 9, 2024

Conference, Webcast

BRANFORD, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (the “Company”) announced today that the Company will release its first quarter 2024 financial results before market open on Friday, May 10, 2024.

Key Points:

BRANFORD, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (the “Company”) announced today that the Company will release its first quarter 2024 financial results before market open on Friday, May 10, 2024.
A webcast and conference call to discuss the results will be held on Friday, May 10, 2024, at 8:00 a.m. Eastern Time.
A webcast of the conference call will be available on the Investors section of the Company’s website www.sachemcapitalcorp.com .
To Participate in the Telephone Conference Call:
Dial in at least 15 minutes prior to the start time.